Tata Laksana Farmakologis Asma


  • Johan Indra Lukito Jakarta, Indonesia




Asma, controller, reliever, terapi


Pengobatan asma bertujuan untuk mencapai kontrol yang baik atas gejala dan untuk meminimalkan risiko eksaserbasi, morbiditas, dan mortalitas. Global Initiative for Asthma (GINA) menganjurkan pendekatan bertahap untuk mencapai kontrol gejala dan kontrol risiko yang terbaik. Pendekatan ini dibagi untuk 3 kelompok usia (5 tahun atau kurang, 6-11 tahun, dewasa atau remaja). Setiap langkah pengobatan mencakup obat utama (controller dan/atau reliever).   Asthma treatment aims to achieve good symptom control and minimize the risk of exacerbations, morbidity, and mortality. Global Initiative for Asthma (GINA) recommends a phased treatment approach with several adjustable steps to achieve the best possible symptom and risk control. This stepped approach is divided into three age groups (5 years or less, 6-11 years, adults or adolescents). Each treatment step includes primary drug (controller and/or reliever).



Download data is not yet available.


WHO. Asthma [Internet]. 2022 [cited 2022 June 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma

Global Initiative for Asthma – GINA. 2022 GINA MAIN REPORT[Internet]. 2022 [cited 2022 June 20]. Available from: https://ginasthma.org/ginareports/

Medscape. Asthma [Internet]. 2022 [cited 2022 June 20]. Available from: https://emedicine.medscape.com/article/296301-overview#a7

de Boer AH, Hagedoorn P, Hoppentocht M, Buttini F, Grasmeijer F, Frijlink HW. Dry powder inhalation: Past, present and future. Expert Opin Drug Deliv. 2017;14(4):499-512

Sharma S, Hashmi MF, Chakraborty RK. Asthma medications [Internet]. 2022 [cited 2022 June 20]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531455/

O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C,et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378:1865-76.

Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380:2020-30.

Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378:1877-87.

Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): A 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet 2019;394:919-28.

Lazarinis N, Jørgensen L, Ekström T, Bjermer L, Dahlén B, Pullerits T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax 2014;69:130-6.

Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356:2040-52.

Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF Jr, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): A randomised, double-blind, placebo-controlled trial. Lancet 2011;377:650-7.

Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: The BASALT randomized controlled trial. JAMA 2012;308:987-97.

Sumino K, Bacharier LB, Taylor J, Chadwick-Mansker K, Curtis V, Nash A, et al. A pragmatic trial of symptom-based inhaled corticosteroid use in African-American children with mild asthma. J Allergy Clin Immunol Pract. 2020;8(1):176-85.

Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2013;4:CD007313

Kew KM, Karner C, Mindus SM, Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2013;12:CD009019.

Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, et al. Beclometasone–formoterol as maintenance and reliever treatment in patients with asthma: A double-blind, randomised controlled trial. Lancet Respir Med. 2013;1:23-31.

Patel M, Pilcher J, Pritchard A, Perrin K, Travers J, Shaw D, et al. Efficacy and safety of maintenance and reliever combination budesonide/formoterol inhaler in patients with asthma at risk of severe exacerbations: A randomised controlled trial. Lancet Respir Med. 2013;1:32-42.

Bateman ED, Harrison TW, Quirce S, Reddel HK, Buhl R, Humbert M, et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respiratory Res. 2011;12:38.

Jorup C, Lythgoe D, Bisgaard H. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. Eur Respir J. 2018;51(1):1701688.

Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004;170:836-44.

Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allerg Clin Immunol. 2002;109:410-8

Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: An evidence-based approach. Med J Aust. 2003;178:223-5.

Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: Systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:2171-80.

Rivington RN, Boulet LP, Côté J, Kreisman H, Small DI, Alexander M, et al. Efficacy of uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. Am J Respir Crit Care Med. 1995;151:325-32

Virchow JC Jr, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000;162:578-85.

Kim LHY, Saleh C, Whalen-Browne A, O'Byrne PM, Chu DK. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: A systematic review and meta-analysis. JAMA. 2021;325:2466-79.

Baan EJ, Hoeve CE, De Ridder M, Demoen L, Lahousse L, Brusselle GG, et al. The ALPACA study: (In)Appropriate LAMA prescribing in asthma: A cohort analysis. Pulm Pharmacol Ther. 2021;71:102074.

Taylor SL, Leong LEX, Mobegi FM, Choo JM, Wesselingh S, Yang IA, et al. Long-term azithromycin reduces Haemophilus influenzae and increases antibiotic resistance in severe asthma. Am J Respir Crit Care Med. 2019;200:309-17.

Walsh LJ, Wong CA, Oborne J, Cooper S, Lewis SA, Pringle M, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001;56:279-84.

Dahl R, Larsen BB, Venge P. Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms. Respir Med. 2002;96:432-8.

American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med. 2007;175:235-42.

Tsiu SJ, Self TH, Burns R. Theophylline toxicity: Update. Ann Allerg. 1990;64:241-57.

Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane database of systematic reviews 2012;5:CD002314.

Food and Drug Administration. FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis [Internet]. 2020 [cited 2022 July 28]. Available from: https://www.fda.gov/drugs/drugsafety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug#:~:text=FDA%20is%20 requiring%20a%20Boxed,allergy%20medicine%20montelukast%20(Singulair).




How to Cite

Lukito, J. I. (2023). Tata Laksana Farmakologis Asma. Cermin Dunia Kedokteran, 50(1), 22–29. https://doi.org/10.55175/cdk.v50i1.335